DXCM Dexcom Inc
Price (delayed)
$88.78
Market cap
$34.69B
P/E Ratio
60.81
Dividend/share
N/A
EPS
$1.46
Enterprise value
$36.62B
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in
Highlights
The stock's price to earnings (P/E) is 47% less than its 5-year quarterly average of 115.4
Dexcom's revenue has increased by 11% YoY
The EPS fell by 16% QoQ but it rose by 4.3% YoY
Dexcom's net income has decreased by 15% from the previous quarter but it has increased by 6% YoY
The quick ratio has declined by 49% year-on-year and by 39% since the previous quarter
The gross margin has declined by 4.3% year-on-year
Key stats
What are the main financial stats of DXCM
Market
Valuations
Earnings
Shares outstanding
390.77M
Market cap
$34.69B
Enterprise value
$36.62B
Price to earnings (P/E)
60.81
Price to book (P/B)
16.49
Price to sales (P/S)
8.66
EV/EBIT
50.3
EV/EBITDA
38.72
EV/Sales
9.08
Revenue
$4.03B
Gross profit
$2.44B
Operating income
$600M
Net income
$576.2M
EBIT
$728M
EBITDA
$945.7M
Free cash flow
$630.7M
Per share
Balance sheet
Liquidity
EPS
$1.46
EPS diluted
$1.42
Free cash flow per share
$1.6
Book value per share
$5.38
Revenue per share
$10.25
TBVPS
$16.15
Total assets
$6.48B
Total liabilities
$4.38B
Debt
$2.53B
Equity
$2.1B
Working capital
$1.37B
Debt to equity
1.2
Current ratio
1.47
Quick ratio
1.22
Net debt/EBITDA
2.03
Margins
Efficiency
Dividend
EBITDA margin
23.4%
Gross margin
60.5%
Net margin
14.3%
Operating margin
14.9%
Return on assets
8.8%
Return on equity
26.3%
Return on invested capital
11.8%
Return on capital employed
20.5%
Return on sales
18.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DXCM stock price
How has the Dexcom stock price performed over time
Intraday
-0.63%
1 week
-0.33%
1 month
2.85%
1 year
-23.72%
YTD
14.16%
QTD
14.16%
Financial performance
How have Dexcom's revenue and profit performed over time
Revenue
$4.03B
Gross profit
$2.44B
Operating income
$600M
Net income
$576.2M
Gross margin
60.5%
Net margin
14.3%
The net margin has decreased by 17% from the previous quarter and by 4% YoY
Dexcom's net income has decreased by 15% from the previous quarter but it has increased by 6% YoY
Dexcom's revenue has increased by 11% YoY
The operating margin has declined by 10% year-on-year and by 6% since the previous quarter
Growth
What is Dexcom's growth rate over time
Valuation
What is Dexcom stock price valuation
P/E
60.81
P/B
16.49
P/S
8.66
EV/EBIT
50.3
EV/EBITDA
38.72
EV/Sales
9.08
The stock's price to earnings (P/E) is 47% less than its 5-year quarterly average of 115.4
The EPS fell by 16% QoQ but it rose by 4.3% YoY
DXCM's P/B is 21% below its 5-year quarterly average of 20.8 and 6% below its last 4 quarters average of 17.6
The company's equity rose by 6% QoQ
The stock's price to sales (P/S) is 44% less than its 5-year quarterly average of 15.4 and 13% less than its last 4 quarters average of 10.0
Dexcom's revenue has increased by 11% YoY
Efficiency
How efficient is Dexcom business performance
Dexcom's ROA has decreased by 16% from the previous quarter but it has increased by 2.3% YoY
The ROE is down by 16% since the previous quarter but it is up by 5% year-on-year
The ROS fell by 10% YoY and by 6% QoQ
Dividends
What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DXCM.
Financial health
How did Dexcom financials performed over time
The company's total assets is 48% higher than its total liabilities
The quick ratio has declined by 49% year-on-year and by 39% since the previous quarter
Dexcom's current ratio has decreased by 48% YoY and by 40% QoQ
The debt is 20% more than the equity
The company's equity rose by 6% QoQ
DXCM's debt to equity is down by 6% QoQ and by 2.4% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.